LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Listă Acțiuni・Sana Biotechnology Inc

Sana Biotechnology Inc

Închisă

SectorSănătate

2.68 0.37

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.6

Maxim

2.71

Indicatori cheie
By Trading Economics
Venit	12M -47M
EPS	-0.171
Angajați	142
EBITDA	23M -35M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+265.67% upside

Dividende
By Dow Jones
Următoarele câștiguri	7 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-68M 893M
Deschiderea anterioară	2.31
Închiderea anterioară	2.68

Sentimentul știrilor

By Acuity

25%

75%

59 / 344 Clasament în Healthcare

Sana Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 iun. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 iun. 2026, 15:41 UTC

Principalele dinamici ale pieței

American Battery Shares Jump on Energy Department Victory

8 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 21:57 UTC

Achiziții, Fuziuni, Preluări

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 iun. 2026, 21:56 UTC

Achiziții, Fuziuni, Preluări

Salesforce Agrees to Buy m3ter

8 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 iun. 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 iun. 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 iun. 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 iun. 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 iun. 2026, 16:55 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 iun. 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 iun. 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 iun. 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 iun. 2026, 16:03 UTC

Achiziții, Fuziuni, Preluări

Orange Bought Stake From Lorca

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Acquires 100% Ownership of MasOrange

8 iun. 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 iun. 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparație

Modificare preț

Sana Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

265.67% sus

Prognoză pe 12 luni

Medie 9.8 USD 265.67%

Maxim 16 USD

Minim 7 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSana Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Sana Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

59 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.